EICHORPublic-registry site landscape for NCT02782663, “A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease”, a Crohn's Disease (CD) study sponsored by AbbVie. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02782663 (registry record) |
| Study title | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease |
| Official title | A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease |
| Sponsor | AbbVie |
| Condition(s) | Crohn's Disease (CD) |
| Phase | PHASE2 |
| Listed sites | 61 |
| Intervention(s) | ABT-494 |
| Site countries | United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand |
Patient-friendly overview of this study: eichor.com/study/NCT02782663.
Eichor generates a preliminary site-risk snapshot for NCT02782663 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
